Precigen Inc (I5X)

Currency in EUR
1.320
-0.014(-1.05%)
Delayed Data·
I5X Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
I5X is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.3201.320
52 wk Range
0.6281.972
Key Statistics
Bid/Ask
1.32 / 1.409
Prev. Close
1.334
Open
1.32
Day's Range
1.32-1.32
52 wk Range
0.628-1.972
Volume
-
Average Volume (3m)
2.41K
1-Year Change
-13.26%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
I5X Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

Precigen Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Precigen Inc Company Profile

Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis; and AG019, which is in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Employees
143
Market
Germany

Compare I5X to Peers and Sector

Metrics to compare
I5X
Peers
Sector
Relationship
P/E Ratio
−3.0x−2.8x−0.5x
PEG Ratio
0.07−0.090.00
Price/Book
−33.0x1.8x2.6x
Price / LTM Sales
110.3x9.3x3.2x
Upside (Analyst Target)
-188.9%41.6%
Fair Value Upside
Unlock26.0%6.0%Unlock

Earnings

Latest Release
May 14, 2025
EPS / Forecast
-0.18 / --
Revenue / Forecast
1.34M / --
EPS Revisions
Last 90 days

I5X Income Statement

People Also Watch

3.15
REPL
+1.61%
11.93
SRPT
-7.38%
4.08
ALT
-0.73%
18.95
URGN
+5.28%
115.62
CRWV
-3.65%

FAQ

What Stock Exchange Does Precigen Inc Trade On?

Precigen Inc is listed and trades on the Frankfurt Stock Exchange stock exchange.

What Is the Stock Symbol for Precigen Inc?

The stock symbol for Precigen Inc is "I5X."

What Is the Precigen Inc Market Cap?

As of today, Precigen Inc market cap is 394.71M.

What Is Precigen Inc's Earnings Per Share (TTM)?

The Precigen Inc EPS (TTM) is -0.56.

From a Technical Analysis Perspective, Is I5X a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Precigen Inc Stock Split?

Precigen Inc has split 0 times.

How Many Employees Does Precigen Inc Have?

Precigen Inc has 143 employees.

What is the current trading status of Precigen Inc (I5X)?

As of 28 Jul 2025, Precigen Inc (I5X) is trading at a price of 1.32, with a previous close of 1.33. The stock has fluctuated within a day range of 1.32 to 1.32, while its 52-week range spans from 0.63 to 1.97.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.